Prior upper endoscopy within 3 years of diagnosis is linked to earlier-stage gastric cancer detection and improved overall ...

GLP-1 RAs for type 2 diabetes significantly lower one-year mortality, especially in those also diagnosed with obstructive sleep apnea.

Achieving sustained virological response after direct-acting antiviral therapy reduces liver-related events among those with decompensated HCV cirrhosis.

The FDA has expanded the approval of Yuflyma (adalimumab-aaty) and its unbranded version to include the treatment of HS in patients aged 12 years and older and UV in pediatric patients aged 2 years ...

The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.

Obeticholic acid added to ursodeoxycholic acid improved alkaline phosphatase and bilirubin levels among patients with PBC unresponsive to first-line therapy.

New code E11.A applies to patients who use lifestyle interventions to show no signs of type 2 diabetes for at least 3 months.

GLP-RAs significantly improved liver histology, liver fat, and metabolic markers in patients with MASLD, outperforming DDP-4 inhibitors but increasing mild GI side effects.

Topline data were announced from two phase 3 trials evaluating orforglipron, an oral GLP-1 receptor agonist, in patients with type 2 diabetes.

Individuals with irritable bowel syndrome have a significantly higher risk of developing ulcerative colitis or Crohn disease.